Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.94 ^USD	+3.19%		-11.01%	-46.26%

May. 10	Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

December 12, 2022 at 08:01 am EST

On December 7, 2022, Joseph Vittiglio informed Finch Therapeutics Group, Inc. of his resignation as the Company's Chief Business and Legal Officer and Secretary, effective as of December 31, 2022, in order to pursue other professional opportunities.

Latest news about Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Top Premarket Decliners	Mar. 12	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Value Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Value Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Index	23-06-23	CI
Top Premarket Decliners	23-06-13	MT
Finch Therapeutics Group Slumps Almost 15% in Premarket Tuesday	23-06-13	MT
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split	23-06-09	MT
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC	23-05-18	CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q1 Revenue $107,000	23-05-10	MT
Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023	23-05-10	CI
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO	23-04-26	MT
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions	23-04-25	CI
Finch Therapeutics Group, Inc. Appoints Lance Thibault as Chief Financial Officer, Effective May 16, 2023	23-04-25	CI
Finch Therapeutics Group, Inc. Announces Executive Changes	23-04-25	CI
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours	23-04-18	MT
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement	23-04-18	CI

Chart Finch Therapeutics Group, Inc.

Duration

Period

More charts

Company Profile

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohnâs disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
FINCH THERAPEUTICS GROUP, INC.	-46.26%	3.12M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+46.96%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research